Tag: Biodexa

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) has seen its stock price experience a remarkable surge following a significant regulatory development. As of the latest premarket check, BDRX shares have risen by 108.40%, trading at $8.48. This increase is attributed to the company’s announcement regarding a crucial regulatory approval.

FDA’s Fast Track Designation for eRapa

Biodexa (BDRX) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to eRapa, a special encapsulated form of rapamycin. The designation aims to speed up the process of creating and evaluating drugs that address significant unmet medical needs and treat severe disorders. Specifically, eRapa is being researched as a treatment for familial adenomatous polyposis (FAP), which often leads to colorectal cancer if left untreated.

FAP and the Requirement for Novel Therapies

A hereditary condition known as FAP causes several polyps to form in the colon and rectum, usually first appearing in adolescence. FAP always develops into colorectal cancer if therapy is not received, and the only available choices are colon and rectum surgical resection. The condition has no approved therapeutic alternatives, making eRapa’s potential a highly significant breakthrough in the field.

Promising Phase 2 Results

Biodexa’s Phase 2 study of eRapa has shown promising results. The drug demonstrated safety and tolerability, with a 17% median reduction in polyp burden after 12 months, compared to baseline measurements.

Notably, 75% of patients in the trial experienced no disease progression. The cohort receiving the preferred dosing regimen of every other day showed even more encouraging outcomes, including an 89% non-progression rate and a 29% median reduction in polyp burden.

Next Steps and Regulatory Designation Plans

In addition to the Fast Track designation, eRapa has already received the FDA’s Orphan Drug status for FAP, and the company plans to seek similar recognition in Europe as it prepares for its upcoming Phase 3 study.

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) shares are going through a remarkable surge on the charts today, rising 14.36% to $4.42, following updates on its transformative acquisitions. BDRX has strategically shifted from being a drug delivery innovator to a therapeutics-focused entity targeting diabetes and cancer treatment.

Biodexa’s Strategic Focus on Repurposed Therapeutics

Biodexa’s approach prioritizes minimizing clinical risk by repurposing molecules with established safety profiles for new applications. Instead of discovering new drugs, BDRX acquires promising products through licensing agreements, bearing development costs while sharing commercialization profits with licensors. This risk-averse model is central to its recent success.

One notable acquisition is eRapa, a potential treatment for familial adenomatous polyposis (FAP), a hereditary condition significantly increasing the risk of colorectal cancer. Currently, FAP patients face limited options, with standard care involving intensive surveillance and eventual surgical removal of the colon. With Phase 2 results demonstrating a 29% median reduction in polyp burden and an 89% non-progression rate in patients following the recommended dosing regimen, eRapa provides a revolutionary option.

Secured Funding and Regulatory Pathway

The Cancer Prevention Research Institute of Texas awarded a $17 million grant to Biodexa’s eRapa initiative, which was augmented by a matching fund. BDRX hopes to submit a New Drug Application (NDA) to the FDA in three years, with finance mainly secured. Recruitment is anticipated to start in early 2025, and preparations are in progress for a “Type C” meeting with the FDA to complete the Phase 3 research protocol.

Expanding the Pipeline

Beyond eRapa, Biodexa is advancing other promising therapeutics. These include a placebo-controlled Phase 2 trial of eRapa for non-muscle invasive bladder cancer (NMIBC) and a Phase 2a dose confirmation study of tolimidone for Type 1 diabetes, which targets pancreatic beta cell regeneration.

Bright Prospects in Rare Diseases

With an orphan drug designation, eRapa could secure exclusivity for seven years in the U.S. and 10 years in Europe. Its peak annual sales potential ranges from $500 million to $1 billion. As Biodexa progresses with pivotal trials and regulatory engagements, it stands poised to make significant contributions to addressing unmet medical needs.

The stock value of Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) saw a significant increase, with shares rising 31.74% to $6.60 during extended trading hours. The disclosure of a noteworthy breakthrough pertaining to the company’s adherence to listing standards on the Nasdaq Stock Market preceded this increase.

Biodexa Succeeded To Get Nasdaq Compliance Extension

Biodexa’s request for an extension to achieve the Nasdaq Listing Rules’ minimum bid price requirement of $1.00 per share has been granted by the Nasdaq Hearings Panel. With this extension, the business has until October 31, 2024, to prove compliance. Biodexa must demonstrate that it can sustain a closing bid price of at least $1.00 per share for a continuous 20 trading days in order to meet this condition.

BDRX Shared Progress in Clinical Trials

In addition to its stock market developments, Biodexa recently provided an update regarding its ongoing Phase 1 clinical study of MTX110 for patients with recurrent glioblastoma. Known as the MAGIC-G1 study, this open-label trial aims to evaluate the feasibility and safety of intermittent infusions of MTX110 administered through convection-enhanced delivery (CED) using an implanted refillable pump and catheter.

MTX110 Trial Results: Patient Status and Survival Rates

As of October 2023, Biodexa announced the successful recruitment of four patients into Cohort A of this study. The current status of the patients is as follows: Patients #1 and #2 have unfortunately passed away, with overall survival (OS) durations of 12 and 13 months, respectively.

Meanwhile, Patients #3 and #4 continue their post-study follow-up, with Patient #3 exhibiting a progression-free survival (PFS) of six months and an OS of 13 months. Patient #4, who has not yet shown confirmed disease progression, has maintained a PFS and OS of 12 months since the commencement of treatment.

Biodexa Pharmaceuticals is poised for a pivotal period as it navigates compliance requirements while advancing its clinical trials, particularly in the challenging area of glioblastoma treatment. The positive stock performance reflects investor confidence in the company’s strategic direction and ongoing research endeavors.